{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-277423","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.750261+00:00","generated_at":"2026-06-22T07:07:54.531755+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PMV Pharma appoints Dr. Carol Gallagher to board, replacing Thilo Schroeder","bullets":["Thilo Schroeder resigned from board effective Nov 3, 2022; resignation not related to any disagreement.","Carol Gallagher, Pharm.D., appointed as Class I director effective Nov 3, 2022.","Gallagher has over 30 years biotech leadership and currently serves as venture partner at NEA.","She joins PMV as the company notes recent clinical proof of concept for lead candidate PC14586."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-277423","json":"https://secwatch.observer/filing/0001193125-22-277423.json","markdown":"https://secwatch.observer/filing/0001193125-22-277423.md","text":"https://secwatch.observer/filing/0001193125-22-277423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522277423/0001193125-22-277423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522277423/d389567d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:07:54.531755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5419c00563","claim":"Carol Gallagher was appointed as Director at PMV Pharmaceuticals, Inc..","evidence_excerpt":"On November 3, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Carol Gallagher, Pharm.D. as a Class I director of the Company to fill the vacancy of Dr. Schroeder’s seat on the Board of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522277423/0001193125-22-277423-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a6ca1fd297","claim":"Thilo Schroeder resigned as Director at PMV Pharmaceuticals, Inc..","evidence_excerpt":"On November 3, 2022, Thilo Schroeder, Ph.D., notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effective on that date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522277423/0001193125-22-277423-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}